Want more claimants? Fill out the form to get free info.
    By submitting this form, I consent that I may be contacted by email and/or phone (including a wireless number) using automated technology, by Adwire Media and/or third-party partners. If I have provided my cell number I also acknowledge that I may be contacted via text message. Message and data rates may apply. My consent is not a requirement for receipt of services.*

    Actemra Criteria

    The criteria below is a list of standard filters. We can customize the criteria based on your requirements.
    • Took Actemra for arthritis (RA, SJIA, PJIA) after 2010
    • Suffered from any of the following while on the medication
      • Heart Attack
      • Stroke
      • Congestive Heart Failure
      • Lung Disease
      • Pancreatitis
    • No legal representation

    Actemra Additional Information


    Genentech (Roche subsidiary)

    Generic Name


    Treatment for

    Rheumatoid and giant cell arthritis drug

    Immuncoresponsive drug

    Actemra is an immunoresponsive drug (IL-6 receptor inhibitors) that was approved in 2010, and has been linked to heart attacks, strokes, interstitial lung disease, heat failure, acute pancreatitis, brain bleeds and other life threatening complications.

    June 2017

    A report by identified thousands of adverse event reports submitted to the FDA over the past seven years, and has been linked to at least 1,128 deaths.


    The Phase 3 clinical study, GIACTA, showed that serious adverse events occurred in 15% (roughly 1:7) patients using Actemra in the study. Competing L-6 receptor inhibitors such as Humira, Enbrel, and Remicade, contain strong warnings against the above side effects. Actemra does not.


    We welcome you to contact Mass Torts USA for more information
    about our products and services.